Immix Biopharma's drug NXC-201 is seeking BLA approval from the FDA and received Orphan Drug Designation from the EMA.
2 reports, 1 independent
Updated Oct 6
Gone quiet
- Reports
- 2
- Developments
- 2
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Immix Biopharma's drug NXC-201 is seeking BLA approval from the FDA and received Orphan Drug Designation from the EMA.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Company targets BLA next year; Morris provides clinical trial results.1 source
- Immix Biopharma's NXC-201 is seeking FDA BLA approval and received EMA Orphan Drug Designation.
Keep exploring
The entities involved
Related events
- BridgeBio plans to submit MAA and NDA for infigratinib review to the FDA.
- Arise is seeking FDA approval for a drug as of October 7, 2026.
- The FDA is reviewing the BLA submission from Ultragenyx Pharmaceutical, with Eric Crombez serving as chief medical officer.
- OS Therapies, Inc. is seeking interim and final review data submissions from regulatory bodies while attending major global investment conferences.
- A company is seeking FDA feedback on its NEO212 program, with a meeting scheduled at the FDA's White Oak campus.
Coverage
Newest first; wire copies grouped- tickerreport.com
- Unknown outlet